Drug-eluting stents articles

Los stents con polímeros biodegradables son tan seguros como los de polímeros permanentes en el seguimiento a 5 años

Biodegradable-polymer stents are as safe as permanent-polymer stents in a 5-year follow-up

Biodegradable-polymer stents are as safe as permanent-polymer stents in a 5-year follow-up

Courtesy of Dr. Carlos Fava. One of the questions around drug-eluting stents (DES) is whether the development of biodegradable polymers would derive in better outcomes than the performance of durable polymers as regards the presence of events. In consequence, the COMPARE II trial was carried out with the aim of testing them in “real-world” patients.   This

DES_angioplastia_primaria

PRISON IV: DES with resorbable polymer vs. DES with permanent polymer in total occlusions

Courtesy of SBHCI. The PRISON IV trial compared the sirolimus eluting stent with ultra-thin struts and biodegradable polymer vs. the second-generation everolimus-eluting stent with thin struts and durable polymer in successfully recanalized chronic total occlusions. This is a sub-study with optical coherence tomography (OCT).   The study included 330 patients, 85% angiographically followed up at

stent

Leaders Free ACS: Good Results for the Polymer-Free Stent at 2 Years in ACS

 Courtesy of the SBHCI. Guidelines recommend dual antiplatelet therapy for a year in patients admitted with coronary acute syndrome. However, patients at high risk for bleeding who receive coronary angioplasty have been historically excluded from studies. The new polymer-free stent BioFreedom allows for the reduction of dual antiplatelet therapy time, due to rapid drug elution

synergy_stent

EVOLVE II: Diabetes Substudy: Results at 3 Years after the SYNERGY Stent in Diabetics

Courtesy of SBHCI Diabetic patients have worse evolution after coronary PCI. Drug eluting stents with bioresorbable polymers were designed to facilitate arterial healing, and reduce inflammation and late and very late thrombosis risk.   This sub-study of diabetic EVOLVE II patients presents the 3 year outcomes of the SYNERGY stent.   The EVOLVE II included

Biodegradable-Polymer Biolimus-Eluting

DESSOLVE III: Xience vs. MiStent

The MiStent device is made of cobalt-chromium, with struts of up to 64 µm thick. It is coated with a completely absorbable polymer that contains a microcrystalline form of sirolimus that embeds directly into the vessel wall. The drug is eluted continuously for up to 9 months.   This was a multicenter noninferiority study that randomized patients

BVS_everolimus

Promising Outcomes of Overlapping Stents in Patients Undergoing Bioresorbable Scaffold (BRS) Implantation

Courtesy of Dr. Guillermo Migliaro. In regular clinical practice, overlapping stents are reported in up to 30% of patients undergoing coronary angioplasty, especially due to very long lesions requiring implantation of multiple stents or dissection after the implantation of a first stent.   In bare metal stent era, overlapping was associated with unfavorable clinical outcomes

Tiempo de doble antiagregación y muerte por sangrado

Dual antiaggregation time and death by bleeding

Despite the fact that some randomized studies and meta-analyzis have suggested prolonged dual antiaggregation could be associated to increased death rate, the underlying mechanism remains unclear. It is only logical to assume that if there was an actual increase in mortality associated to prolonged antiaggregation, this should be due to bleeding; however, no studies have

Stent directo vs angioplastia convencional y sus interacciones con la trombo-aspiración

Bioresorbable scaffolds with drug-eluting stents: do they entail a higher thrombosis risk?

Courtesy of Dr. Leiva. Bioresorbable scaffolds with drug-eluting stents (bioresorbable vascular scaffolds, BVS) have been added to the list of endovascular treatment options for coronary disease. The ABSORB III trial showed the non-inferiority of this stent type to everolimus-eluting metallic stents as regards target-lesion revascularization (TLR) at one year. However, reports have suggested a higher

absorv vs xience acc 2017

ABSORB III: More Events with Absorb Than With Xience at Two Years

The two year outcomes of ABSORB III, presented at the scientific sessions of the American College of Cardiology 2017, have shown the bioresorbable scaffold Absorb GT1 (BVS, Abbott Vascular) was associated with increased risk of target vessel failure, compared against the everolimus eluting stent Xience.   At 25 months, target vessel failure occurred in 11%

Stents liberadores de biolimus y everolimus

Biolimus and Everolimus Eluting Stents in Coronary Artery Disease: Similar Safety?

Courtesy of Dr. Guillermo Migliaro. Events such as very late stent thrombosis and restenosis after first generation DES stenting were associated to the inflammatory response of site implantation. The presence of a durable or permanent polymer was thought to play a central role in said inflammatory process, which caused, among other things, delayed re-endothelialization and

IVUS en las lesiones coronarias complejas

Why We Should Use IVUS in Complex Coronary Lesions

Courtesy of Dr. Carlos Fava. Drug eluting stents (DES) have shown benefits in terms of restenosis vs. conventional bare metal stents (BMS). Many of the advantages of DES depend on correct implantation, especially in complex lesions.   In complex lesions, the use of intravascular ultrasound (IVUS) provides important information on lesion length, vessel diameter, calcification

Top